A good knee visit starts with an exam and straight questions

The exam should come before the procedure

You'll show the examiner where the knee hurts and explain when it began. Expect some walking and bending, then questions about swelling or lost support.

Take every medicine name with you, and mention old injuries or past procedures. QC Kinetix offers regenerative treatments, meaning blood-based, non-surgical procedures discussed after its medical provider examines the joint and reviews your past health.

Wear shoes you can walk in, and carry notes if the ache comes and goes. Small details are easy to forget once the visit starts.

Your health history can change the choice

The medicine talk must cover blood thinners, bleeding trouble, infection, and hard-to-control blood sugar. Mention plans for joint replacement and any bad reaction after an earlier procedure.

Ask what goes into the knee, who performs the procedure, and when relief may begin. Get the total price and clear next steps if the knee doesn't improve.

Ask whether you'll need a driver or a quieter day afterward. You'll also want a phone number for new swelling or much worse soreness.

Some knee problems need urgent care

Get prompt help when a swollen knee feels hot and you have fever, weakness, or numbness. Fast swelling after an injury or worsening heat after a procedure can't wait either.

Those signs may mean infection, a broken bone, or a serious injury inside the knee. If the change is severe or moving fast, use emergency care instead of a routine visit.

Sources

1. The 2019 ACR/Arthritis Foundation OA guideline makes a STRONG recommendation for intra-articular glucocorticoid injection in knee OA, alongside strong recommendations for exercise, weight loss, self-management, tai chi, cane use, bracing and NSAIDs; intra-articular steroid injection for HAND OA is only conditionally recommended.

   Kolasinski SL, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.. Arthritis Rheumatol, 2020. DOI: 10.1002/art.41142.

2. The 2015 Cochrane review of 27 trials (1,767 participants) found intra-articular corticosteroid better than sham for knee OA pain (SMD -0.40, 95% CI -0.58 to -0.22; NNTB 8), but the benefit decayed with time: moderate at 1-2 weeks, small at 13 weeks, and no evidence of any effect at 26 weeks. All outcomes were graded LOW quality.

   Jüni P, et al. — Intra-articular corticosteroid for knee osteoarthritis.. Cochrane Database Syst Rev, 2015. DOI: 10.1002/14651858.CD005328.pub3.

3. In a 2-year double-blind RCT of 140 patients with symptomatic knee OA and ultrasound synovitis, 40 mg intra-articular triamcinolone every 12 weeks produced significantly greater cartilage volume loss than saline (index compartment cartilage thickness change -0.21 mm vs -0.10 mm; between-group difference -0.11 mm, 95% CI -0.20 to -0.03) with no significant difference in knee pain.

   McAlindon TE, et al. — Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.. JAMA, 2017. DOI: 10.1001/jama.2017.5283.

4. A meta-analysis of 10 RCTs of RECURRENT intra-articular corticosteroid injections (2-8 injections per patient) found they often gave inferior or non-superior relief compared with hyaluronic acid, PRP, saline or orgotein at 3 months and beyond, and no benefit over placebo in pain or function at 12-24 months.

   Donovan RL, et al. — Effects of recurrent intra-articular corticosteroid injections for osteoarthritis at 3 months and beyond: a systematic review and meta-analysis in comparison to other injectables.. Osteoarthritis Cartilage, 2022. DOI: 10.1016/j.joca.2022.07.011.

5. In the Osteoarthritis Initiative cohort (684 propensity-matched participants), knees whose owners started intra-articular corticosteroids had radiographic OA worsening at 21.7 per 100 person-years versus 7.1 in comparators; the hazard ratio for Kellgren-Lawrence worsening was 3.02 for initiation, higher still for continuous use.

   Zeng C, et al. — Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative.. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.01.007.

6. FDA's HCT/P guidance sets out the minimal-manipulation and homologous-use criteria that decide whether a human cell or tissue product is regulated solely under 21 CFR Part 1271 (section 361) or requires a biologics licence; cell-based orthopaedic injections that fall outside those criteria are unapproved drugs and biological products, and no cell-based product is FDA-approved to treat osteoarthritis.

   U.S. Food and Drug Administration — Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use - Guidance for Industry and FDA Staff. U.S. Food and Drug Administration, 2020.